Received Aug 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 5H95B | — |
patient's 2nd dose of DTaP and 2nd dose of IPV; 3-year-old child received Kinrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate schedule of vaccine administered in a 3-year-old female patient who received DTPa-IPV (Kinrix) (batch number 5H95B, expiry date 16-FEB-2026) for prophylaxis. On 15-MAY-2025, the patient received the 1st dose of Kinrix. On 15-MAY-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate schedule of vaccine administered (Verbatim: patient's 2nd dose of DTaP and 2nd dose of IPV) and inappropriate age at vaccine administration (Verbatim: 3-year-old child received Kinrix). The outcome of the inappropriate schedule of vaccine administered and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 24-JUL-2025 and 25-JUL-2025 Nurse called to report the administration of a shot of Kinrix and mentioned that she was aware that the vaccine is indicated for ages 4 to 6 years and wanted to know if a new vaccine is needed or if this dose. Upon callback, HCP stated that Kinrix was the patient's 2nd dose of DTaP and 2nd dose of IPV and that Prior to the administration of Kinrix vaccine, patient received Vaxelis (Dtap-ipv-hep b).